Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Neoadjuvant chemoradiation in locally advanced triple negative breast cancer patients: 4 cycles of 3 weekly chemotherapy with anthracycline cyclophosphamide followed by 12 weekly cycles
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Biopsy proven unilateral locally advanced triple negative breast cancer which includes Stage IIIA-C &/or oligometastastic disease which is defined by ESTRO/ESMO/ACOG as a disease with up to 5 lesions each amenable to local therapy aimed at achieving no evidence of disease status.
Exclusion criteria
Exclusion criteria: Unwilling for mastectomy, previous irradiation to chest wall, multiple visceral/bone metastasis, renal cardiac dysfunction, uncontrolled diabetes, bilateral breast cancer, recurrence of tumour
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the tolerability of treatment regimenTimepoint: Patient will be assessed at baseline, during time of chemoradiation, post surgery,and after treatmet at 6 weeks, 8 weeks and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess pathological complete response rate (pCR)Timepoint: pCR report will be available only post surgery (after completion of treatment i.e Neoadjuvant chemoradiation followed by modified radical mastectomy) single time point | — |
Countries
India
Contacts
Public ContactJahnabi Das
Dr B Borooah Cancer Institute
Outcome results
None listed